DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Seymour S.
Division Summary: Overview of the FDA background materials for New Drug Application (NDA) 22-535, Esbriet (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce the decline in lung function.
In: Seymour S, ed.
FDA Briefing Information for the March 9, 2010 Meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC). NDA 22-535.
Washington, D.C.: US Food and Drug Administration; 2010: 2-20 Available from:
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf [accessed 2010 May 10]
We do not assume any responsibility for the contents of the web pages of other providers.